Phase IV Study of Respiratory Syncytial Virus Monoclonal Antibody Therapy in High-risk Infants and Toddlers
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 14 Sep 2017
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Therapeutic Use
- 08 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 01 Nov 2016 Results (n=19235) assessing palivizumab adherence and outcomes in aboriginal versus non-aboriginal children receiving palivizumab in the Canadian Registry of palivizumab (CARESS) database (2005-2014), published in the Pediatric Infectious Disease Journal.
- 06 Oct 2016 Results (n=1909) assessing differences in respiratory-illness related hospitalization (RIH) and respiratory syncytial virus (RSV) specific infection hospitalization (RSVH) in HSCHD infants receiving palivizumab during the first versus second year of life in the Canadian Registry of palivizumab (CARESS) database (2005-2015), published in the Pediatric Infectious Disease Journal..